Page last updated: 2024-08-25

rosiglitazone and Morbid Obesity

rosiglitazone has been researched along with Morbid Obesity in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Fernández-Real, JM; Moreno-Navarrete, JM; Ortega, F; Ricart, W; Sabater, M; Sánchez-Garrido, MÁ; Tena-Sempere, M; Zorzano, A	1
Kadioglu, M; Kalyoncu, NI; Kesim, M; Ulku, C; Yaris, E; Yaris, F	1
Brunani, A; Castagna, G; Caumo, A; Graci, S; Liuzzi, A; Viberti, G	1

Trials

1 trial(s) available for rosiglitazone and Morbid Obesity

Article	Year
Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non-diabetic patients. Diabetes, obesity & metabolism, 2008, Volume: 10, Issue:6 Topics: Adipose Tissue; Adolescent; Adult; Aged; B-Lymphocytes; Blood Glucose; Body Composition; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Male; Metformin; Middle Aged; Obesity; Obesity, Morbid; Rosiglitazone; Thiazolidinediones; Weight Loss	2008

Article

Year

Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non-diabetic patients.

Diabetes, obesity & metabolism, 2008, Volume: 10, Issue:6

Topics: Adipose Tissue; Adolescent; Adult; Aged; B-Lymphocytes; Blood Glucose; Body Composition; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Male; Metformin; Middle Aged; Obesity; Obesity, Morbid; Rosiglitazone; Thiazolidinediones; Weight Loss

2008

Other Studies

2 other study(ies) available for rosiglitazone and Morbid Obesity

Article	Year
Phosphorylated S6K1 (Thr389) is a molecular adipose tissue marker of altered glucose tolerance. The Journal of nutritional biochemistry, 2013, Volume: 24, Issue:1 Topics: Adipocytes; Adipose Tissue; Adipose Tissue, White; Animals; Biomarkers; Blotting, Western; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression; Glucose Tolerance Test; Humans; Insulin Receptor Substrate Proteins; Male; Obesity, Morbid; Phosphorylation; Rats; Rats, Wistar; Reference Values; Reproducibility of Results; Ribosomal Protein S6 Kinases; Ribosomal Protein S6 Kinases, 70-kDa; Rosiglitazone; Thiazolidinediones; Threonine	2013
Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman. Reproductive toxicology (Elmsford, N.Y.), 2004, Volume: 18, Issue:4 Topics: Adult; Anxiety Disorders; Apgar Score; Atorvastatin; Chronic Disease; Diabetes Complications; Epilepsy; Female; Gliclazide; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Hypoglycemic Agents; Infant, Newborn; Obesity, Morbid; Pregnancy; Pregnancy Complications, Cardiovascular; Pregnancy Outcome; Pyrroles; Rosiglitazone; Thiazolidinediones	2004

Article

Year

Phosphorylated S6K1 (Thr389) is a molecular adipose tissue marker of altered glucose tolerance.

The Journal of nutritional biochemistry, 2013, Volume: 24, Issue:1

Topics: Adipocytes; Adipose Tissue; Adipose Tissue, White; Animals; Biomarkers; Blotting, Western; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression; Glucose Tolerance Test; Humans; Insulin Receptor Substrate Proteins; Male; Obesity, Morbid; Phosphorylation; Rats; Rats, Wistar; Reference Values; Reproducibility of Results; Ribosomal Protein S6 Kinases; Ribosomal Protein S6 Kinases, 70-kDa; Rosiglitazone; Thiazolidinediones; Threonine

2013

Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman.

Reproductive toxicology (Elmsford, N.Y.), 2004, Volume: 18, Issue:4

Topics: Adult; Anxiety Disorders; Apgar Score; Atorvastatin; Chronic Disease; Diabetes Complications; Epilepsy; Female; Gliclazide; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Hypoglycemic Agents; Infant, Newborn; Obesity, Morbid; Pregnancy; Pregnancy Complications, Cardiovascular; Pregnancy Outcome; Pyrroles; Rosiglitazone; Thiazolidinediones

2004